For many men, lower urinary tract symptoms (LUTS) linked to benign prostatic hyperplasia (BPH) gradually become a major quality-of-life concern. Frequent nighttime urination, hesitancy, urgency, and incomplete emptying are more than just inconveniences—they affect sleep, daily energy, and general wellbeing.
When symptoms become bothersome, one of two well-known approaches are often applied: alpha-blockers, a class of medications, and the extract of Serenoa repens, a specific plant extract used for prostate wellbeing. A recent French real-world study —the PERSAT sub-analysis— offers an unusually clear comparison of how men respond to each over a period of six months.
What Did the Study Look At?
The sub-analysis comes from the PERSAT study, which followed 759 men with moderate to severe urinary symptoms related to BPH. For this particular analysis, scientists focused on the 633 men who stayed on the same treatment—either:
- an alpha-blocker, or
- the hexanic extract of Serenoa repens (HESr).
At the start, both groups had similar symptom scores (average IPSS around 18), which makes the comparison meaningful. The study took place in everyday general-practice settings across France—so the results reflect real life, not the controlled conditions of a clinical trial.
How Well Did Each Approach Work?
After six months, the results were strikingly similar across both groups. Almost all men improved—93.7% with HESr and 94.8% with alpha-blockers—reaching the level of symptom change that typically feels noticeable in everyday life. Symptoms eased substantially too: IPSS scores fell by roughly 10 points on average for both approaches. In men who started out with more severe discomfort (IPSS above 19), the improvements were even greater, with drops of 13.6 and 14.8 points, respectively. SerRep&AB
Quality of life rose in parallel. Whether men used HESr or an alpha-blocker, they reported a similar boost in day-to-day comfort, reflected in a nearly identical improvement in their IPSS-QoL scores. And importantly, this wasn’t just a numerical shift—over 95% of both patients and their doctors described a clear overall improvement in wellbeing.
What About Side Effects?
This is where the two options differed more clearly. Alpha-blockers were associated with more reported side effects, particularly ejaculation-related changes and episodes of low blood pressure or dizziness. Overall, 18.5% of men on alpha-blockers experienced some form of side effect.
In contrast, men taking the hexanic extract of Serenoa repens reported fewer issues: only 6.7% noted any side effect, most commonly mild digestive discomfort.
Why This Study Matters
The PERSAT sub-analysis shows that in everyday practice:
- Both approaches offer similar symptom relief
- Both help men feel better and live more comfortably
- The main difference is tolerability, with fewer side effects reported for the hexanic extract of Serenoa repens
This is useful information when discussing options with a healthcare professional, especially if long-term comfort and day-to-day quality of life are priorities.
Phytotherapy’s Place in Prostate Wellbeing
For many men, there is growing interest in incorporating botanical extracts into their daily wellbeing routines—especially those traditionally associated with urinary comfort, such as Serenoa repens. Modern formulations often combine this extract with other synergistic plants, chosen for their complementary roles in maintaining normal urinary function, supporting tissue balance, or contributing antioxidant properties.
This type of multi-extract approach aligns well with what we see in contemporary phytotherapy: synergy, where carefully selected botanicals may offer broader, more holistic support than any single ingredient alone. As research continues to expand, these comprehensive plant-based blends are becoming a meaningful part of how men choose to look after long-term prostate wellbeing within a natural and lifestyle-focused framework.
REFERENCES
de la Taille A, Chalret du Rieu Q, Dialla O, Bardin L. Alpha-bloquants ou extrait hexanique de Serenoa repens pendant 6 mois : sous-analyse de l’étude PERSAT [Alpha-blockers or hexanic extract of Serenoa repens for 6 months: sub-analysis of the PERSAT study]. Prog Urol. 2023 Feb;33(2):66-72. French.